BioMarin Pharmaceutical Expects Q3 Pre-Tax Charges Of $283M For Bought IPR&d Expense; Expects $1.5 Unfavorable Impact To GAAP And Non-gaap Diluted EPS For Q3; Expects Total Pre-Tax Charges Of $320M For FY26 From Alesta Acquisition; Expects $1.55 Unfavorable Impact To GAAP And Non-Gaap Diluted EPS For FY26

BioMarin Pharmaceutical anticipates pre-tax charges of $283 million for Q3 due to acquired IPR&D expenses, which will negatively impact GAAP and non-GAAP diluted EPS by $1.5. For the fiscal year 2026, the company expects total pre-tax charges of $320 million related to the Alesta acquisition, leading to a projected unfavorable impact of $1.55 on GAAP and non-GAAP diluted EPS.